Trial reportClinical oral investigations2025
"Clinical and radiological evaluation of periodontal intrabony defects treated with DFDBA and 1% melatonin gel and its effect on RANKL and OPG in gingival crevicularfluid - a randomized controlled trial".
Trial report in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to evaluate and compare the effectiveness of 1% melatonin gel combined with demineralized freeze-dried bone allograft (DFDBA) versus DFDBA alone in treating intrabony periodontal defects in Stage II & III periodontitis. Clinical and radiographic outcomes were assessed using cone-beam computed tomography (CBCT), along with analysis of gingival crevicular fluid (GCF) levels of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG). METHODOLOGY: A prospective, randomized, controlled, single-blinded clinical trial was conducted on 20 patients with 20 intrabony defects. The control group received DFDBA alone, while the test group received a combination of 1% melatonin gel and DFDBA. Clinical parameters Clinical Attachment Level (CAL) and Probing Pocket Depth (PPD) were evaluated at baseline, 3, and 6 months. Using cone beam computed tomography (CBCT) radiographic parameters linear bone fill and bone volume and GCF biomarkers (RANKL and OPG) were assessed at baseline and 6 months. Plaque Index (PI) and Sulcus Bleeding Index (SBI) were secondary outcomes. CAL change served as the primary outcome variable.
resultsAfter 6 months, the test group showed a mean CAL gain of 3.10 ± 0.87 mm and the control group 4.00 ± 1.85 mm, which was not statistically significant between the groups; however, intra-group comparison revealed a statistically significant CAL gain from baseline in both groups. Both groups showed improvements in assessed parameters, however, the test group demonstrated significantly greater bone fill (1.88 ± 0.26 mm vs. 1.16 ± 0.38 mm) and bone volume gain (22.67 ± 1.36 mm³ vs. 14.78 ± 0.5 mm³; p< 0.000). Greater reduction in PPD and gain in CAL were noted in the test group. GCF analysis revealed a significant increase in OPG (99.87 ± 15.07) and reduction in RANKL levels (66.13 ± 19.12) in the test group at 6 months (p= 0.000).
conclusionMelatonin gel as an adjunct to DFDBA enhances clinical, radiographic, and biochemical outcomes in intrabony periodontal defect therapy. Clinical Trials Registry of India (CTRI/2023/07/055039).
Indexed as
Identifiers
41205053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.